Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Non-Current Assets (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Non-Current Assets for 13 consecutive years, with $230366.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 95.7% year-over-year to $230366.0, compared with a TTM value of $230366.0 through Dec 2025, down 99.06%, and an annual FY2025 reading of $230366.0, down 95.7% over the prior year.
  • Non-Current Assets was $230366.0 for Q4 2025 at Abvc Biopharma, down from $17.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $17.9 million in Q3 2025 and bottomed at $230366.0 in Q4 2025.
  • Average Non-Current Assets over 5 years is $4.5 million, with a median of $3.3 million recorded in 2021.
  • The sharpest move saw Non-Current Assets skyrocketed 2239.97% in 2024, then crashed 95.7% in 2025.
  • Year by year, Non-Current Assets stood at $374423.0 in 2021, then fell by 18.84% to $303893.0 in 2022, then decreased by 17.5% to $250716.0 in 2023, then surged by 2037.91% to $5.4 million in 2024, then plummeted by 95.7% to $230366.0 in 2025.
  • Business Quant data shows Non-Current Assets for ABVC at $230366.0 in Q4 2025, $17.9 million in Q3 2025, and $13.5 million in Q2 2025.